Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2000-03-31
2010-06-22
Huynh, Phuong (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
C424S141100, C424S142100, C424S143100
Reexamination Certificate
active
07740841
ABSTRACT:
A method of controlling or treating an angiogenic dependent condition in a mammal, preferably in a human by administering an anti-angiogenic molecule such as an angiogenesis growth factor antagonist, and a chemotherapeutic agent in amounts and frequencies effective, in combination, to produce a regression or arrest of said condition while minimizing or preventing significant toxicity of the chemotherapeutic agent. Also a kit for controlling or treating an angiogenic dependent condition in a mammal, preferably in a human, comprising an anti-angiogenic molecule, such as an angiogenesis growth factor antagonist, and a chemotherapeutic agent in amounts effective, in combination, to produce a regression or arrest of said condition while minimizing or preventing significant toxicity of the chemotherapeutic agent.
REFERENCES:
patent: 4853221 (1989-08-01), Elslager et al.
patent: 4946778 (1990-08-01), Ladner et al.
patent: 5036003 (1991-07-01), Olander et al.
patent: 5190198 (1993-03-01), Cucheran
patent: 5190918 (1993-03-01), Cucheran
patent: 5192744 (1993-03-01), Bouck et al.
patent: 5200397 (1993-04-01), Deutch et al.
patent: 5399667 (1995-03-01), Frazier et al.
patent: 5399677 (1995-03-01), Wolfman et al.
patent: 5506208 (1996-04-01), Eyal et al.
patent: 5648461 (1997-07-01), Eval et al.
patent: 5652109 (1997-07-01), Kim et al.
patent: 5652110 (1997-07-01), Kim et al.
patent: 5654277 (1997-08-01), Eyal et al.
patent: 5659013 (1997-08-01), Senger et al.
patent: 5660827 (1997-08-01), Thorpe et al.
patent: 5684461 (1997-11-01), Jones
patent: 5696131 (1997-12-01), Baguley et al.
patent: 5696153 (1997-12-01), Ainsworth et al.
patent: 5730977 (1998-03-01), Ooka et al.
patent: 5753230 (1998-05-01), Brooks et al.
patent: 5759996 (1998-06-01), Cheng et al.
patent: 5767071 (1998-06-01), Palladino et al.
patent: 5770195 (1998-06-01), Hudziak et al.
patent: 5770563 (1998-06-01), Roberts et al.
patent: 5773412 (1998-06-01), Cheng et al.
patent: 5780426 (1998-07-01), Palladino et al.
patent: 5840301 (1998-11-01), Rockwell et al.
patent: 5840692 (1998-11-01), Deutch et al.
patent: 5855866 (1999-01-01), Thorpe et al.
patent: 5861499 (1999-01-01), Rockwell et al.
patent: 5874542 (1999-02-01), Rockwell et al.
patent: 5877289 (1999-03-01), Thorpe et al.
patent: 5919792 (1999-07-01), Duggan et al.
patent: 5952341 (1999-09-01), Duggan et al.
patent: 5955311 (1999-09-01), Rockwell et al.
patent: 5965132 (1999-10-01), Thorpe et al.
patent: 5981546 (1999-11-01), Duggan et al.
patent: 6004555 (1999-12-01), Thorpe et al.
patent: 6017925 (2000-01-01), Duggan
patent: 6017926 (2000-01-01), Askew et al.
patent: 6100254 (2000-08-01), Budde et al.
patent: 6302838 (2001-10-01), O'Reilly et al.
patent: 6342219 (2002-01-01), Thorpe et al.
patent: 6824777 (2004-11-01), Alitalo et al.
patent: 6884879 (2005-04-01), Baca et al.
patent: 0 239 400 (1987-03-01), None
patent: 0 239 400 (1987-03-01), None
patent: 0 332 424 (1989-03-01), None
patent: 0 332 424 (1989-03-01), None
patent: 0 338 745 (1989-04-01), None
patent: 0 506 477 (1992-03-01), None
patent: WO 89/09622 (1989-10-01), None
patent: WO 92/14748 (1992-09-01), None
patent: WO 93/21319 (1993-10-01), None
patent: WO 9521868 (1995-08-01), None
patent: WO 97/05250 (1997-02-01), None
patent: WO 97/05250 (1997-02-01), None
patent: WO 98/33917 (1998-08-01), None
patent: WO 99/16465 (1999-04-01), None
patent: WO 00/34337 (2000-06-01), None
patent: WO 00/51686 (2000-09-01), None
patent: WO 00/69459 (2000-11-01), None
Lokieh et al., Am J Clinical Oncology 7(5): 551-3, Oct. 1984.
Jackson et al., Cancer chemotherapy and pharmacology 10(3): 217-20, 1983.
Obrist et al., Cancer chemotherapy and pharmacology 2(4): 233-37, 1979.
Klement et al., J Clinical Investigation 105(8) : R15-R23, Apr. 2000.
Stryer et al, in Biochemistry, Third edition, W H Freeman Company, New York, pp. 31-33, 1998.
Ngo et al, 1994, The Protein Folding Problem and Tertiary Structure Prediction, pp. 492-495.
Abaza et al, J of Protein Chemistry 11(5): 433-444, 1992.
Fogarty et al, The Scientist 16(16): 33, Mar. 2002.
Jakobovits et al, Advanced Drug Delivery Reviews 31: 33-42, 1998.
Glade-Bender et al, Exp Opinion Biol Ther 3(2): 263-276, 2003.
Witte et al, Cancer Metastasis Rev 17(2): 155-61, Jun. 1998.
Baca et al, J Biol Chem 272(16): 10678-10684, 1997.
Folkman et al, Forum 9(3): 59-223, 1999.
Vassal et al, Int J Cancer 73: 156-163, 1997.
Teicher et al, Breast Cancer Research and Treatment 36: 227-236, 1995.
Weitman et al, J Clinical Oncology 11(5): 820-821, May 1993.
N. Takahashi et al., “Antiangiogenic Therapy of Established Tumors in Human Skin/Severe Combined Immunodeficiency Mouse Chimeras by Anti-Endoglin (CD105) Monoclonal Antibodies, and Synergy between Anti-Endoglin Antibody and Cyclophosphamide” Cancer Research 61, Nov. 1, 2001, pp. 7846-7854.
L. Bello et al., “Low-dose Chemotherapy Combined with an Antiangiogenic Drug Reduces Human Glioma Growth in Vivo”, Cancer Research 61, Oct. 15, 2001, pp. 7501-7506.
G. Klement et al., “Differences in Therapeutic Indexes of Combination Metronomic Chemotherapy and an Anti-VEGFR-2 Antibody in Multidrug-resistant Human Breast Cancer Xenografts”, Clinical Cancer Research, vol. 8, Jan. 2002, pp. 221-232.
L. Zhang et al., “Combined Anti-Fetal Liver Kinase 1 Monoclonal Antibody and Continuous Low-Dose Doxorubicin Inhibits Angiogenesis and Growth of Human Soft Tissue Sarcoma Xenografts by Induction of Endothelial Cell Apoptosis”, Cancer Research 62, Apr. 1, 2002, pp. 2034-2042.
Baringa, Angiogenesis Research: Cancer Drugs Found to Work in New Way, Science Apr. 14, 2000 (288) 5464 p. 245.
Fidler et al., Chemotherapeutic drugs—more really is not better, Nature Medicine May 2000 (6)5, pp. 500-502.
Hanahan et al., Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice, J. Clin. Invest. Apr. 2000, 105(8), pp. 1045-1047.
Kamen et al., High-Time Chemotherapy or High Time for Low Dose, Journal of Clinical Oncology, Aug. 18, 2000 (16) pp. 2935-2937.
Breier et al., Development (Camb.) 114:521 (1992).
Klagsburn, M. and D'Amore, P. Annual Rev. Physiol. 53:217-239 (1991).
Kozbor et al., Immunology Today 4:72, (1983).
Database WPI , Section Ch, Week 199828 Derwent Publications Ltd., London, GB; An 1998-316701 XP002286349, May 6, 1998.
Tortora G et al., “Oral Administration of Chimeric MBO Antisense-Protein Kinase a Inhibits Growth, Angiogenesis and Growth Factors Production and Cooperates With Cytotoxic Drugs in Human Cancer Xenografts” European Journal of Cancer, Pergamon Press, Oxford, GB vol. 35, No. Suppl. 4, Sep. 1999, XP008004191.
Sola F. et al., “The antitumor efficacay of cytotoxic drugs is potentiated by treatment with PNU 145156E, a growth -factor-complexing molecule” Cancer Chemotherapy and Pharmacology, Springer Verlag, Berlin, DE, vol. 43, No. 9, pp. 241-246, 1999.
Yamaoka M. et al., “Angiogenesis Inhibitor TNP-470 (AGM-1470) Potently Inhibits the Tumor Growth of Hormone-Independent Human Breast and Prostate Carcinoma Cell Lines” Cancer Research, American Association for Cancer Research, Baltimore, MD, US, vol. 53, pp. 5233-5236, Nov. 1, 1993, XP001064890.
Kerbel R.S. et al. “Establishing a link between oncogenes and tumor angiogenesis” Molecular Medicine, Blackwell Science, Cambridge, MA, US vol. 4, No. 5, pp. 286-295, May 1, 1998, XP002089417.
Klement G. et al., “Continous Low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression iwthout overt toxicity” Journal of Clinical Investigation, New York, NY, US, vol. 105, No. 8, pp. R15-R24, Apr. 2000, XP002269717.
Kerbel R.S., et al., “Accidental' Anti-angiogenic drugs: Anti-ONcogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples” European Journal of Cancer, vol. 36, No. 10, pp. 1248-1257, Jun. 2000, XP002286348.
Folkman, J. and Klagsbrun, M., Science, vol. 235, pp. 442-447, Jan. 1987, “Angiogenic Factors”.
Brown, L. F. et al., J. Ex
Huynh Phuong
Lucas & Mercanti LLP
Sunnybrook Health Science Center
LandOfFree
Therapeutic method for reducing angiogenesis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic method for reducing angiogenesis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic method for reducing angiogenesis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4156072